Key Takeaways
- Volume-led revenue surge, margin softens: Revenue grew +36% YoY on higher volumes, but EBITDA margin slipped 146 bps YoY with no specific driver disclosed.
- Capacity ceiling reached: Utilization sits at ~95%, so volume growth from existing processes is capped until the new CAPEX facilities come online.
- ₹200 crore CAPEX cycle begins: A multi-year expansion into APIs and fermentation, funded by internal accruals, aims to break the capacity constraint and open regulated export markets.
- Business model shift still paying off: The move from cost-plus contract manufacturing to own-manufacturing-and-sales in FY20 structurally lifted realizations and margins, a tailwind now fully embedded.
- What to watch next quarter: Whether the API block commissioning timeline holds, the pace of customer diversification beyond the top two, and any demand signal from upcoming Rifaximin patent expiries.
Capacity & the CAPEX Cycle
- 95% utilized, growth capped: With existing fermentation assets nearly full, volume growth from current processes is limited until new facilities arrive; management is exploring alternative strategies for volume growth beyond the next couple of quarters.
- ₹200 crore phased build-out: The plan spans two to three years and covers three elements: a multi-purpose API block, expanded fermentation capacity (three plants), and a strengthened R&D infrastructure.
- API block first, fermentation later: The API block is expected online by end of Q2 FY24; the fermentation block follows the year after, with construction starting by December.
- API block strategy, fast entry then integrate: The block will initially produce APIs from sourced intermediates to accelerate market entry, while the company builds its own fermentation capabilities and files products from the CGMP pilot.
- Regulatory ambition: The API plant will be a fully GMP-compliant facility targeting the US FDA, domestic market, and other regulated markets.
- Funding posture: The CAPEX will be funded primarily through internal accruals, with debt available as an option; the balance sheet currently carries zero debt and a reasonably good cash surplus.
Dr. Sachin Patel: "in our past experience there is a significant challenge to scale up. So one may do something at a particular level, starting from lab to even pilot, but then to scale it up to commercial scale and be able to be competitive in terms of the market has its fair set of challenges and experiences required"
Product & Customer Dynamics
- Rifaximin and Rifa both contributing: Rifaximin is doing well, and Rifa (Rifampicin) is also performing, though the tuberculosis tender business creates quarter-to-quarter lumpiness when tenders are delayed.
- Rifa O variability tied to macro, not demand: When selling Rifa O to customers who convert it into Rifaximin for global markets, currency turmoil and debtor issues cause quantity variations quarter-to-quarter, even when underlying demand is intact.
- Customer concentration, early diversification: Three new customers have been onboarded for Rifa S, but volumes remain very small as most capacity is occupied by the top two customers.
- No preference, deliberate spread: Management aims to spread quantities across customers to ensure flexibility and secure the best contracts, with no preference for one over another.
- Lovastatin shelved: The product remains with GTBL but is not currently produced for economic reasons.
- Spot business minimized: Most business is conducted through long-term partners with contractual obligations on both sides, reducing exposure to spot-market volatility.
Dr. Sachin Patel: "I think on both sides, there are no immediate solutions and that is why relationships are what they are. I would say that we would not have too many options. I would believe that they would not have too many options."
Margin & Pricing
- Margin decline unexplained: EBITDA margin fell 146 bps YoY in Q2 and 118 bps in H1; management offered no specific reason for the compression.
- No price increases planned: Pricing is bound by contractual obligations on both sides, and no increases are envisaged at this stage.
- Margin outlook deliberately vague: Management hopes margins remain at current levels but calls any definitive forecast speculation on future pricing, which it will not offer.
- API block margins structurally lower: Margins from the API block are not expected to be in line with fermentation margins, so the mix shift will be a headwind to blended profitability.
- Product selection as margin defense: The company may have a dozen products in development but is very careful about what it takes commercial, prioritizing profitability over breadth.
Dr. Sachin Patel: "I wish I could tell you that we can maintain the margins or even grow them. But you know, that would be an indirect way of you asking me what is the pricing going to be tomorrow or day after. So, that will be a bit of a speculation from all our end..."
Competitive Position & Strategy
- No complacency on competition: Management acknowledges potential threats from China and elsewhere on pricing or competition, calling complacency unwarranted.
- Scale-up as a moat: The challenge of scaling fermentation from lab to pilot to commercial, while remaining cost-competitive, is a significant barrier that experience helps navigate.
- Mutual dependency with customers: Management believes neither side has too many immediate alternatives, which underpins the stability of existing relationships and contracts.
- Forward integration into APIs: The CAPEX plan includes developing an API block, with decisions on whether to manufacture the API or only the intermediate made case-by-case based on value proposition; flexibility to do both is the priority.
- Multi-product, not single-product bet: The future strategy is spread across multiple projects and products rather than tied to any one molecule, providing resilience.
- Value-capture discipline: Management has mapped where maximum value sits in the supply chain for current products and believes the company is positioned at that point; forward integration will be selective.
Dr. Sachin Patel: "I think, for any of us to be complacent and think that there is no potential threat be it from China or anywhere else in terms of pricing or in terms of competition is a bit too complacent."
Demand Outlook & Patent Triggers
- Patent expiries as a volume catalyst: Patent expiries are expected to drive volumes up in the generic space, but management is still assessing how that will specifically impact overall Rifa demand.
- Two-year demand visibility unclear: The company is working to understand whether Rifa S or Rifa O demand will increase two years out, but cannot yet speculate on the direction or magnitude.
- Rifaximin demand stable but not immune: While Rifaximin is a fairly stable business, macro factors like currency turmoil and debtor issues can still create quarter-to-quarter quantity variations.
- Tuberculosis tender lumpiness: Underlying patient demand for tuberculosis treatments remains, but quarter-to-quarter revenue can vary if tenders do not open on time.
- Growth during the capacity bridge: Management is working on multiple strategies to grow over the next eight quarters even though fermentation capacity will take longer; API capacity coming online next year should definitely increase the top line and hopefully the bottom line.
Dr. Sachin Patel: "...there is a lot of turmoil that is happening across the world right in terms of currencies, in terms of dollar to the local currency. So sometimes the demand may be there, but because of reasons of debtors, etc, you may have a variation in terms of quantity supply from one quarter to another quarter."
Corporate Developments
- Themis Medicare stake acquisition withdrawn: The proposed acquisition of GTBL shares by Themis Medicare from PBG was subsequently withdrawn; Themis Medicare is not acquiring the shares.
- PBG ownership stable: PBG owns 51% of GTBL shares, and the promoters of PBG are essentially the same as they have been for a very long time.
- No stake acquired from PBG: Management clarified GTBL has not acquired any stake from PBG.
- NSE listing on track: The net worth criterion of over ₹100 crores for three consecutive years is expected to be fulfilled next year; management states the company should be most definitely listing on NSE after that.
- Warehouse imminent: The warehouse will be capitalized and put to use in Q3 FY23.
- R&D center delayed: The R&D center originally envisaged to initiate in Q3 FY23 has been postponed to the next quarter.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| API block commissioning | Multi-purpose API block expected online | End of Q2 FY24 |
| Fermentation block construction start | Three plants, phased over two to three years | Construction starts by December |
| Fermentation block commissioning | Fermentation block operational | The year after the API block |
| Warehouse capitalization | Warehouse put to use | Q3 FY23 |
| R&D center initiation | R&D center operational start | Postponed to next quarter (Q4 FY23) |
| NSE listing | Net worth criterion of >₹100 cr for 3 consecutive years fulfilled | Next year |
| CAPEX funding | ₹200 crore funded primarily by internal accruals; debt optional | Over the two-to-three-year CAPEX period |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹47.69 cr, +36.08% YoY, driven by higher volumes |
| EBITDA | ₹24.4 cr, +32.29% YoY |
| EBITDA margin | 51.17%, down 146 bps YoY |
| PAT | ₹18.7 cr, vs ₹13.79 cr in Q2 FY22 |
| Net profit margin | 39.21% |
| EPS | ₹12.87 per share |
| H1 FY23 revenue | ₹92.64 cr, +37.26% YoY, driven by rising volumes |
| H1 FY23 EBITDA | ₹47.18 cr, +34.15% YoY |
| H1 FY23 EBITDA margin | 50.93%, down 118 bps YoY |
| H1 FY23 PAT | ₹36.47 cr, vs ₹26.71 cr in H1 FY22 |
| H1 FY23 net profit margin | 39.37% |
| H1 FY23 EPS | ₹25.10, +36.48% YoY |
| Capacity utilization | 95% |
| CAPEX plan | ₹200 cr, spread over 2–3 years, funded primarily through internal accruals |
| CAPEX spent to date | ~₹22 cr, mostly in CWIP |
| API plant cost | ~₹40 cr, expected commissioning end of Q2 FY24 |